Literature DB >> 20732832

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

Jasvir Dhillon1, Koen Andries, Patrick P J Phillips, Denis A Mitchison.   

Abstract

The bactericidal activities of the diarylquinoline TMC207 in a liquid culture medium started with a bacteriostatic phase lasting about 7 days and then continued with a dose-related bactericidal phase. In comparison, its intra-cellular activity in primary mouse peritoneal macrophages (PM) and in the J774 macrophage-like cell line had little or no static phase so that the bactericidal kill was evident by 5-7 days presumably due to low bacterial ATP levels. Bactericidal activities in the three systems were compared by estimating the rate of bacterial killing (K) during exposure to 0.12-1.0 μg/ml TMC207 which were similar at, -0.35 in the J774 cells and -0.27 in mouse PM (p = 0.6) with each lower than -0.11 in extra-cellular cultures (p < 0.001) and [2] the TMC207 concentration at the intersection between the curve relating cfu count to TMC207 concentration and the cfu count at day-0, defined as the static concentration. Static concentrations were 0.22 μg/ml for extra-cellular cultures, 0.17 μg/ml for mouse PM and 0.06 μg/ml for J774 cells, significantly lower than the extra-cellular value (p < 0.001). Thus, the intra-cellular activity of TMC207 is clearly greater than its extra-cellular activity mainly because the preliminary static phase was a shorter or absent.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732832     DOI: 10.1016/j.tube.2010.07.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  18 in total

1.  Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.

Authors:  Rosemary V Swanson; John Adamson; Chivonne Moodley; Bongani Ngcobo; Nicole C Ammerman; Afton Dorasamy; Sashen Moodley; Zinhle Mgaga; Asa Tapley; Linda A Bester; Sanil Singh; Jacques H Grosset; Deepak V Almeida
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

2.  Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro.

Authors:  E D Pieterman; M J Sarink; C Sala; S T Cole; J E M de Steenwinkel; H I Bax
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  The chemotherapy of tuberculosis: past, present and future.

Authors:  D Mitchison; G Davies
Journal:  Int J Tuberc Lung Dis       Date:  2012-06       Impact factor: 2.373

4.  After 40 years, new medicine for combating TB.

Authors:  Mehdi Mirsaeidi
Journal:  Int J Mycobacteriol       Date:  2013-03

Review 5.  Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

Authors:  Stephen K Field
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

6.  Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.

Authors:  Marie-Claude Rouan; Nacer Lounis; Tom Gevers; Lieve Dillen; Ron Gilissen; Araz Raoof; Koen Andries
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

Review 7.  Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis.

Authors:  Sabine Ehrt; Dirk Schnappinger; Kyu Y Rhee
Journal:  Nat Rev Microbiol       Date:  2018-08       Impact factor: 60.633

8.  Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.

Authors:  Kristin N Adams; John D Szumowski; Lalita Ramakrishnan
Journal:  J Infect Dis       Date:  2014-02-14       Impact factor: 5.226

9.  Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.

Authors:  Robert S Wallis; Wesley Jakubiec; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Darcy Paige; Annette Silvia; Paul F Miller
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

10.  In Vitro Profiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis.

Authors:  Gauri S Shetye; Kyung Bae Choi; Chang-Yub Kim; Scott G Franzblau; Sanghyun Cho
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.